IPCI Intellipharmaceutics Internatio

1.89
+0  (0%)
Previous Close 1.89
Open 1.90
Price To book 65.17
Market Cap 57.43M
Shares 30,386,000
Volume 258,142
Short Ratio 6.90
Av. Daily Volume 323,648

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date September 25, 2017.
Rexista
Pain relief

Latest News

  1. Intellipharmaceutics Reports Director Election Results
  2. Intellipharmaceutics International, Inc. :IPCI-US: Earnings Analysis: Q1, 2017 By the Numbers : April 14, 2017
  3. IntelliPharmaCeutics (IPCI) Q1 Loss Narrower Than Expected
  4. Intellipharmaceutics reports 1Q loss
  5. Intellipharmaceutics Announces First Quarter 2017 Results
  6. Intellipharmaceutics Announces Patent Litigation by Purdue against its Rexista™ Abuse-Deterrent Extended-Release Oxycodone
  7. Intellipharmaceutics International, Inc. :IPCI-US: Earnings Analysis: 2016 By the Numbers : March 22, 2017
  8. Nektar Pharma Opioid Drug Shows Promise In Phase 3
  9. Intellipharmaceutics Announces TSX Trading Symbol Change to “IPCI”
  10. Monday Movers In Biotech: Cempra Inc (CEMP) And IntelliPharmaCeutics Intl Inc (USA) (IPCI)
  11. Biotech's Rise Shows No Sign of Slowing Down in 2017: Today's Reports on IntelliPharmaCeutics and Orexigen Therapeutics
  12. Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage® XR
  13. Intellipharmaceutics Announces 2016 Year End Results
  14. Intellipharmaceutics Painkiller Qualifies for FDA Review
  15. Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain